What are the recent trends in market size and growth for the varizig market?
The varizig market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to growth in healthcare expenditure, growth in the prevalence of organ transplantation procedures, rise in government funding for immunization programs, growth in the geriatric population, and growth in private insurance coverage.
The varizig market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to growing incidence of chickenpox, rising investments in the development of varicella-related biologics, growing demand for immune globulin products, increasing public health initiatives, and rising clinical trials. Major trends in the forecast period include technological advancements, adoption in global humanitarian, advancements in recombinant DNA technology, development of novel formulations, and telemedicine.
Get Your Free Sample of The Global VariZIG Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20448&type=smp
How have varous drivers impacted the growth of the varizig market?
The increase in the incidence of varicella-zoster virus infections is expected to drive the varizig market going forward. The varicella-zoster virus (VZV) is a highly contagious virus that causes chickenpox as the primary infection and can reactivate later in life to cause shingles (herpes zoster). The increase in the incidence of varicella-zoster virus (VZV) infections, leading to conditions such as chickenpox and shingles, can be attributed to reduced vaccination rates, an aging population, and immune suppression due to medical treatments. varizig helps varicella-zoster virus patients by providing passive immunity, reducing the severity and duration of chickenpox symptoms, preventing complications in high-risk individuals such as immunocompromised patients, and offering protection against severe outcomes in neonates and pregnant women exposed to the virus. For instance, in November 2024, according to the Florida Department of Health, a US-based government agency, in 2023, the number of varicella cases increased to 653, compared to 428 cases in 2022. Therefore, the rising incidence of varicella-zoster virus infections drives the varizig market.
What are the primary segments of the varizig market?
The varizig market covered in this report is segmented –
1) By Patient Condition: Immunocompromised Patients; Pregnant Women
2) By Distribution Channel: Hospitals; Pharmacies; Healthcare Providers
3) By End User: Adult; Geriatric; Pediatric
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/varizig-global-market-report
Which firms are leading the varizig market?
Major companies operating in the varizig market are Emergent BioSolutions Inc.
How will industry trends affect the trajectory of the varizig market?
The key trend in the varizig market is securing supply agreements to the product for high-risk patient populations, expanding distribution channels, and meeting the growing demand for passive immunization, particularly in emergency and high-exposure scenarios. Supply agreements are contracts between parties that outline the terms and conditions for providing goods or services, including pricing, delivery schedules, and responsibilities of each party. For instance, in July 2022, Kamada Ltd., an Israel-based biopharmaceutical company, announced an $11.4 million procurement agreement to supply its product VARIZIG to an undisclosed international organization primarily operating in Latin America. The supply is expected to take place from the fourth quarter of 2022 through the first half of 2023. This agreement reflects Kamada’s strategy to expand its sales of FDA-approved plasma-derived therapies in international markets, highlighting the commercial potential beyond North America. VARIZIG is specifically indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk groups, such as immunocompromised patients and newborns, making it a crucial therapeutic option for these populations.
Which geographic trends are shaping the varizig market, and which region has the highest market share?
North America was the largest region in the varizig market in 2024. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The VariZIG Market Report 2025 Offer?
The varizig market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
VariZIG is a hyperimmune globulin derived from human plasma with high antibodies against the varicella-zoster virus (VZV). It is used as a post-exposure prophylaxis to reduce the severity of chickenpox in high-risk individuals, such as immunocompromised patients, pregnant women, and newborns. Administered intramuscularly, it provides passive immunity by delivering pre-formed antibodies. Varizig is most effective when given within 96 hours of VZV exposure.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20448
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
